On April 6, 2026 Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, reported that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, CA, from April 17 – 22, 2026. The presentations demonstrate Biodesix capabilities in blood- and tissue-based testing and monitoring across a range of applications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Biodesix expertise in test discovery and development, regulatory, reimbursement, and commercialization provides an exceptional level of service for our partners across a range of applications. The AACR (Free AACR Whitepaper) presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts. The data are reinforced by more than a decade of experience supporting the clinical development and commercialization of new diagnostics and therapeutics," said Gary Pestano, PhD, Chief Scientific Officer, Biodesix.

"The depth of experience and success across the Biodesix team, spanning real-world clinical care and cutting-edge research, will be on full display at this year’s AACR (Free AACR Whitepaper). It is especially exciting to see our genomic and proteomic technologies, combined with advanced data informatics, translating into meaningful clinical impact in our pipeline product concepts while also fueling strong momentum in our Development Services business as we move into 2026," said Scott Hutton, CEO, Biodesix.

Tumor & Immune Profiling Expertise

Biodesix oral and poster presentations highlight diverse technology platforms, rapid turn-around times for our clinical tests, and extensive capabilities in immune and tumor profiling using mass spectrometry, Bio-Rad Droplet Digital PCR, and Thermo Fisher Ion AmpliSeq platforms. In addition, Biodesix has validated a new clinical myeloid panel on the Thermo Fisher Ion Torrent Genexus System. The platform supports an automated clinical next-generation sequencing (NGS) workflow and can deliver sequencing results in as little as 24 hours.

Sunday, April 19 | 3PM–5PM PST​ | Oral Presentation | Room 17, Mezzanine Level, Convention Center
​Title: Real-world analysis of NSCLC* variant-level frequencies from liquid biopsy testing in diverse U.S. populations​

Monday, April 20 | 2PM–5PM PST | Poster Section 41
Poster: 3743. ddPLEX EGFR/KRAS/BRAF: A highly multiplexed droplet digital PCR (ddPCR) panel for ultra-sensitive NSCLC biomarker detection

Wednesday, April 22 | 9AM–12PM PST​ | Poster Section 39​
Poster: Blood-based proteomic profiling reveals novel biomarkers of Neuroendocrine Prostate Cancer​

Monday, April 20 | 2PM–5PM PST​ | Poster Section 44​
Title: Performance validation of a next generation sequencing myeloid assay on an integrated nucleic acid purification and sequencing system​

Molecular Residual Disease (MRD) Product Pipeline

Another set of presentations highlights a novel, multi-omic approach to MRD monitoring. Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center will co-present new data on proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline tests.

Monday, April 20 | 12:30PM | Spotlight Theater B – Sails Pavilion – Conv Ctr
Title: Leveraging Droplet Digital PCR* (ddPCR) for MRD Detection and Monitoring in Solid Tumors and Heme Malignancies

Tuesday, April 21 | 2PM–5PM PST​ | Poster Section 1​
Poster: 5437. Sensitive detection of rare cfDNA variants utilizing molecular technologies and a novel informatics platform: A combined genomic and proteomic MRD application.​

​Wednesday, April 22 | 9AM–12PM PST​ | Poster Section 45​
Poster: 7828. Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive molecular residual disease (MRD) detection using diverse tumor profiling inputs​

The full abstracts for Biodesix and a list of all abstracts being presented at the AACR (Free AACR Whitepaper) Annual Meeting can be found here.

ddPCR technology is a trademark of Bio-Rad Laboratories, Inc.
Ion Torrent Genexus System and Ion AmpliSeq Platform are trademarks of Thermo Fisher Scientific.
NSCLC is the acronym for Non-Small Cell Lung Cancer.

(Press release, Biodesix, APR 6, 2026, View Source [SID1234664192])

On April 6, 2026 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 8,400 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.

(Press release, Abeona Therapeutics, APR 6, 2026, View Source [SID1234664177])

On April 6, 2026 Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, reported that it will present three posters at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, which is being held from April 17-22, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentations will include preclinical data for the company’s two lead programs, FX-909, a first-in-class, orally available PPARG inhibitor designed to target the underlying luminal lineage biology of urothelial cancer and FX-111, a novel and highly differentiated potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor for prostate cancer.

FX-909 Presentation Details:

Luminal urothelial carcinoma (UC), characterized by high PPARG expression, represents the majority of UC cases and is associated with poor clinical outcomes. In a Phase 0 study, FX-909, a first-in-class oral PPARG inhibitor, demonstrated intratumoral penetration and on-target activity, including dose-dependent PPARG modulation, increased tumor apoptosis, and enhanced CD8⁺ T-cell infiltration. Notably, combination with anti-PD-1 further amplified immune activation and suppression of tumor proliferation pathways. These findings support the potential of FX-909 to modulate the tumor microenvironment and warrant further clinical evaluation in UC.

Title: Phase 0 Intratumoral Microdevice Study of FX-909 in Bladder Cancer Demonstrates On-Target Anti-Tumor Activity and Immune Modulation, Enhanced in Combination with Anti-PD-1

Abstract ID: CT111 / 3
Session: Phase 0 and First-in-Human Phase I Clinical Trials
Date, Time: April 20, 2026, 2:00 p.m. – 5:00 p.m. PT
Location: Section 51
FX-111 Presentation Details:

Metastatic castration-resistant prostate cancer (mCRPC) remains largely driven by androgen receptor (AR) signaling, with resistance to current AR inhibitors posing a major clinical challenge. Real-world data identified distinct AR/KLK3-defined subgroups, with AR copy number amplification linked to increased AR signaling and poorer outcomes, reinforcing the central role of AR-driven biology in disease progression and identifying a high-risk, AR-driven population.

Title: AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC)

Abstract ID: 3910 / 16
Session: Molecular Targeted Therapy
Date, Time: April 20, 2026, 2:00 p.m. – 5:00 p.m. PT
Location: Section 47
FX-111 is a novel and highly differentiated, potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor. This approach offers the potential to overcome key vulnerabilities of conventional therapies that target AROFF, particularly in high-risk AR-driven disease, and has broad potential across prostate cancer at all stages.

Title: Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androgen receptor (ARON), to treat patients with AR-driven prostate cancer

Abstract ID: 5784 / 11
Session: Proximity-Induced Drug Discovery 2
Date, Time: April 21, 2026, 2:00 p.m. – 5:00 p.m. PT
Location: Section 15

(Press release, Flare Therapeutics, APR 6, 2026, View Source [SID1234664193])

On April 6, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, reported the publication of two abstracts that will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will present previously undisclosed data demonstrating the expanding potential of its Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies. Both presentations will occur on April 21, 2026 in the session Radiopharmaceutical Platforms for Theranostic Precision Oncology.

Sandesh Seth, Actinium’s Chairman and CEO, said, "These new data further validate the strength and versatility of our Ac-225 radiotherapy platform. ATNM-400 continues to show compelling pan-tumor activity, including activity in tumors resistant to current targeted therapies, supporting its potential as a first-in-class asset in large solid tumor indications. In parallel, Actimab-A’s newly identified mechanism of transcriptional reprogramming provides important insight into its mutation-agnostic activity and ability to enhance standard-of-care therapies. Together, these findings reinforce our strategy to build a differentiated pipeline with multiple value-driving opportunities."

ATNM-400 AACR (Free AACR Whitepaper) 2026 Presentation Details

Poster Number: 5824

Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology

Date & Time: April 21, 2026 – 2:00 PM – 5:00 PM PT | Poster Section 16, Board #18

Actimab-A AACR (Free AACR Whitepaper) 2026 Presentation Details

Poster Number: 5827

Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology

Date & Time: April 21, 2026 – 2:00 PM – 5:00 PM PT | Poster Section 16, Board #21

(Press release, Actinium Pharmaceuticals, APR 6, 2026, View Source [SID1234664178])

On April 6, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") reported a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q1 2026 Highlights

Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter.
FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed.
Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-quarter. Strong revenue growth in both Illuccix and Gozellix segments.
ProstACT Global Phase 3 study of TLX591-Tx prostate cancer therapy candidate: Part 1 lead-in met safety and dosimetry objectives, with no new safety signals observed1.
TLX101-Px (brain cancer imaging candidate): New Drug Application (NDA) resubmitted to the United States (U.S.) Food and Drug Administration (FDA)2 for Pixclara3. Marketing Authorization Application (MAA) filed in Europe4 for Pixlumi3.
TLX591-Px5: NDA accepted in China by the National Medical Products Administration (NMPA)6.

Q1 2026 Revenue (Unaudited)

Revenue (US$M) Q1 2026 Q1 2025 Variation Q4 2025 Variation
Group revenue 230 186 24% 208 11%
Precision Medicine revenue7 186 151 23% 161 16%
TMS third-party revenue8 44 34 29% 44 —%

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, "Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two‑product PSMA9 imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter."

Therapeutics Business Unit

Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q1 2026 highlights include:

TLX591-Tx (lutetium (177Lu) rosopatamab tetraxetan): Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate, achieved its study objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed1. No adverse drug-drug interactions were observed in TLX591-Tx combinations, demonstrating the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC10, including ARPIs11 (enzalutamide or abiraterone) and docetaxel. Telix has commenced engagement with the FDA to present data from Part 1 and ascertain eligibility for U.S. patients to participate in Part 2 (randomized treatment expansion). Part 2 is open for enrollment in Australia, New Zealand and Canada, with site activation underway in preparation to open enrollment in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan, where regulatory approvals have already been granted.
TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan): Telix has opened its first clinical site and is recruiting patients for Part 1 of LUTEON12, a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC13. Trial recruitment will initially focus ex-U.S.
TLX101-Tx (131I-iodofalan): Telix has enrolled the first patient in IPAX-BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma14. The trial is now open for enrollment in Australia, Austria and the Netherlands and has received regulatory approval to commence in Belgium.
TLX090-Tx (153Sm-DOTMP): Telix continues to dose patients in SOLACE15, a Phase 1 study of a drug candidate for treating pain in patients with osteoblastic bone metastases from prostate and breast cancers. The study was expanded this quarter to include additional U.S. sites to accelerate recruitment.
TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA): TLX597-Tx is a "next generation" PSMA-targeting prostate cancer therapy candidate being developed to facilitate patient access in select geographies, where routine clinical availability to approved therapies is limited or not available. Early clinical data suggests a favorable asset biodistribution with limited uptake in healthy organs of concern (e.g., salivary glands, kidneys) relative to available 177Lu-PSMA therapies. Interim data from OPTIMAL-PSMA16, an investigator-led, randomized, dose intensification study of TLX597-Tx in mCRPC, will be presented at the International Prostate Cancer Symposium in April 2026.

Precision Medicine Business Unit

PSMA imaging portfolio:

Telix continues to expand its commercial footprint with Illuccix now launched in 21 countries globally, which includes 16 countries in Europe. This growing international presence enhances access to PSMA-PET/CT imaging17 while establishing a scalable commercial and operational platform to support future product launches, including follow-on therapeutic products.
Telix’s broad proposed label for TLX591-Px (Illuccix) is under review by the NMPA Centre for Drug Evaluation as part of the NDA submission18.

TLX101-Px, (Floretyrosine F 18 or 18F-FET):

Telix has resubmitted its NDA in the U.S. with the additional clinical data and analysis as agreed with the FDA.
Telix has submitted a MAA in Europe covering commercially significant markets, seeking to expand patient access to advanced brain imaging.

Zircaix3 (TLX250-Px, 89Zr-DFO-girentuximab):

Based on two successful Type A meetings with the FDA, Telix believes it has aligned on key outstanding issues for the Biologics License Application (BLA) resubmission, including demonstration of drug product comparability between clinical trial material and scale-up commercial production. The Company is now completing the agreed deliverables and documentation required, targeting a H1 2026 submission.

Corporate Updates

Telix has announced the appointment of David Gill as Non-Executive Director (NED), effective May 11, 2026, as part of its Board renewal process19. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as NED. The Board believes Mr. Gill’s appointment will enhance the Board’s capability, with extensive experience in U.S. public company governance, financial oversight and senior leadership across commercial and clinical-stage biopharmaceutical companies.

FY 2026 guidance

Telix reaffirms FY 2026 revenue guidance of US$950 million to US$970 million20.
Guidance reflects revenue from product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS.
Telix reaffirms research and development (R&D) expenditure guidance of US$200 million to US$240 million, subject to achieving ongoing global commercial milestones.

(Press release, Telix Pharmaceuticals, APR 6, 2026, View Source [SID1234664194])